Tradegate
20.11.25 | 19:27
5,450 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,450 | 5,550 | 22:09 | |
| 5,400 | 5,600 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 6 | City A.M. | ||
| 12.11. | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 263 | Business Wire | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat... ► Artikel lesen | |
| 06.11. | Silence Therapeutics: EPS übertrifft Schätzungen um 0,04 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 06.11. | Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M | 2 | Seeking Alpha | ||
| 06.11. | Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 4 | City A.M. | ||
| 06.11. | Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 344 | Business Wire | SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
Silence Therapeutics plc, Nasdaq:... ► Artikel lesen | |
| 06.11. | Silence Therapeutics plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11. | Silence Therapeutics plc - 8-K, Current Report | 2 | SEC Filings | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.10. | Silence Therapeutics plc - 8-K, Current Report | 5 | SEC Filings | ||
| 23.10. | Silence Therapeutics completes enrollment in PV treatment study | 3 | Investing.com | ||
| 23.10. | Silence Therapeutics plc: Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) | 265 | Business Wire | Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26
Silence Therapeutics plc (Nasdaq: SLN), a global... ► Artikel lesen | |
| 02.09. | Silence Therapeutics plc: Silence Therapeutics to Participate in September Investor Conferences | 400 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate... ► Artikel lesen | |
| 07.08. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.08. | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 359 | Business Wire | Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
Silence... ► Artikel lesen | |
| 07.08. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 27.06. | Silence Therapeutics plc - 8-K, Current Report | 4 | SEC Filings | ||
| 13.06. | H.C. Wainwright reiterates buy rating on Silence Therapeutics stock | 20 | Investing.com | ||
| 12.06. | Silence Therapeutics plc: Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera | 658 | Business Wire | Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded... ► Artikel lesen | |
| 08.05. | Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 1.323 | Business Wire | Company further extends cash guidance into 2028
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)... ► Artikel lesen | |
| 06.05. | Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors | 569 | Business Wire | Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors
Silence Therapeutics plc... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 40,450 | +3,49 % | Novo Nordisk: Knallharter Preiskampf | Die Börsenwoche steht unter keinem guten Stern. Der DAX rutscht heute weiter ab. Zuletzt mehrten sich Befürchtungen, dass der große Hype um Aktien aus dem Segement Künstliche Intelligenz (KI) zu einer... ► Artikel lesen | |
| GILEAD SCIENCES | 109,42 | +0,66 % | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 369,60 | +0,45 % | VERTEX PHARMACEUTICALS INC stürzt ab - Alarmstufe Rot! | ||
| INNOCAN PHARMA | 7,650 | -4,97 % | Innocan Pharma berichtet über vielversprechende Ergebnisse aus der Verabreichung von LPT-CBD an Göttinger Minischweine, ein bekanntes Tiermodell in der Arzneimitteltoxikologie | Herzliya, Israel und Calgary, Alberta - 20. November 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP40) (OTCQB: INNPD)
("Innocan" oder das "Unternehmen"), ein Vorreiter auf... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 69,54 | +2,02 % | With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis | ||
| SNDL | 1,491 | -3,24 % | SNDL renews share repurchase program | ||
| ASSEMBLY BIOSCIENCES | 31,800 | -3,05 % | Assembly Biosciences +367%: Showdown zum Jahresende? | Es ist eine Kursrallye aus dem Bilderbuch: Die Aktie von Assembly Biosciences läuft seit Monaten auf Hochtouren, markierte bei 36,22 US$ gestern ein neues Langzeithoch. Der jüngste Quartalsbericht zeigt:... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,050 | +1,94 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Release Date for Third Quarter Results | Toronto, Ontario--(Newsfile Corp. - November 18, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 373,60 | -0,88 % | Alnylam's ATTR cardiomyopathy drug backed for NHS use | ||
| LIGAND PHARMACEUTICALS | 176,00 | -2,22 % | Ligand Pharma: RBC bekräftigt "Outperform"-Rating vor Investorentag | ||
| PROMINO NUTRITIONAL SCIENCES | 0,034 | -100,00 % | Promino Nutritional Sciences Inc (2): Promino files corrective disclosure after OSC review | ||
| DARE BIOSCIENCE | 1,780 | -0,56 % | Daré Bioscience, Inc.: Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update | DARE to PLAY Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued... ► Artikel lesen | |
| HYTN INNOVATIONS | 0,064 | 0,00 % | HYTN sichert sich Cannabis-Arzneimittellizenz und erzielt Fortschritte im Zulassungsverfahren für verschreibungspflichtige Arzneimittel für Medikamente auf Cannabinoidbasis | Vancouver, British Columbia - 14. Juli 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
führendes Unternehmen in der Herstellung... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,640 | 0,00 % | TuHURA Biosciences: Shelf-Registrierung wird wirksam | ||
| WAVE LIFE SCIENCES | 6,350 | -2,31 % | Wave Life Sciences Ltd.: Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update | WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding... ► Artikel lesen |
SILENCE THERAPEUTICS PLC ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 5,450 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.